Telisotuzumab Vedotin
Last Updated: 11/08/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 44 publications
Cost-Effectiveness of Telisotuzumab Vedotin-tllv for Previously Treated High c-Met Protein-Overexpressing Nonsquamous Non-Small Cell Lung Cancer in the United States.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: May 12, 2026
Targeting MET in 2025: From Exon 14 Skipping to MET-Amplified Acquired Resistance in Non-Small Cell Lung Cancer.
Journal: International journal of molecular sciences
Published: May 01, 2026
An evaluation of telisotuzumab vedotin for the treatment of non-squamous non-small cell lung cancer.
An evaluation of telisotuzumab vedotin for the treatment of non-squamous non-small cell lung cancer.
Journal: Expert opinion on biological therapy
Published: April 29, 2026
Neurotrophic Keratitis Associated With Telisotuzumab Vedotin: A Case Report.
Journal: Cornea
Published: April 13, 2026
MET Expression in Upper Gastrointestinal Adenocarcinoma: Prevalence, Prognostic Impact, and Implications for Anti-MET Antibody-Drug Conjugate Therapy.
Journal: International journal of cancer
Published: March 12, 2026
Antibody-drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation.
Journal: ESMO open
Published: March 10, 2026
Population Pharmacokinetics and Exposure-Response Analyses for Telisotuzumab Vedotin in Patients With c-Met Protein Overexpressing Tumors.
Journal: CPT: pharmacometrics & systems pharmacology
Published: January 29, 2026
Prevalence of antibody drug conjugated-induced nausea and vomiting (ADCINV) in patients with cancer.
Prevalence of antibody drug conjugated-induced nausea and vomiting (ADCINV) in patients with cancer.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: January 17, 2026
Emerging landscape of antibody-drug conjugates in lung cancer: a clinical review.
Journal: Trends in cancer
Published: January 12, 2026
Emrelis: A New Approach in Treating MET-high Locally Advanced or Metastatic Non-squamous NSCLC; A Mini Review.
Journal: Thoracic research and practice
Published: December 29, 2025
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial.
Journal: JTO clinical and research reports
Published: October 21, 2025
Emrelis for c-Met Positive NSCLC: A Breakthrough in Antibody-Drug Conjugate-based Treatment Approved by the FDA.
Journal: Anti-cancer agents in medicinal chemistry
Published: September 11, 2025
Last Updated: 11/08/2026